# Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

> **NCT06593600** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 82 (actual)

## Conditions studied

- Postural Orthostatic Tachycardia Syndrome (POTS)

## Interventions

- **DRUG:** REGN7544
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06593600
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-13
- **Primary completion:** 2026-04-13
- **Final completion:** 2026-07-06
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06593600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06593600, "Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06593600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*